Monday, July 28, 2014 Last update: 3:33 AM
FreshNews.com - All Company Technology News Since 1996

Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2012 Financial Results

Companies mentioned in this article: Onyx Pharmaceuticals, Inc.

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/21/13 -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the full year and fourth quarter 2012 and provided a business update.

"This past year was transformational, as Onyx grew from a company with one therapy in two indications to one with three therapies approved in four indications and positive Phase 3 data for another two potential indications," said N. Anthony Coles, M.D., chairman and chief executive officer of Onyx. "We enter 2013 with the architecture for near-term momentum in our business and sustained growth. The successful launch of Kyprolis, Onyx's first wholly-owned product, serves as the foundation of our emerging proteasome inhibitor franchise, and we are committed to investing in a broad Phase 3 clinical development program across all lines of therapy to reach more patients globally. 2013 will be an important year for commercial execution in the United States, while developing select capabilities to expand our business internationally."

Dr. Coles continued, "The second launch of 2012 was Bayer's Stivarga with additional regulatory actions expected this year in the United States, Europe and Japan. Contributions from worldwide sales of Nexavar and royalty revenue from Stivarga provide increasing cash flow to enable the strategic investment in Kyprolis and oprozomib."

Onyx reported total revenue of $362.2 million for the full year 2012 and $127.9 million for the fourth quarter 2012. Onyx reported non-GAAP net loss of $162.9 million, or $2.50 per diluted share, for the full year 2012 and $24.0 million, or $0.36 per diluted share, for the fourth quarter 2012. On a GAAP basis, Onyx reported net loss of $187.8 million, or $2.88 per diluted share, for the full year 2012 and $42.9 million, or $0.64 per diluted share, for the fourth quarter 2012. A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Financial Measures."

Revenue
For the full year and fourth quarter of 2012, Onyx reported total revenue of $362.2 million and $127.9 million, respectively, as compared to total revenue of $447.2 million and $237.0 million for the comparable periods in 2011. For the full year and fourth quarter of 2011, total revenue included $160.0 million in contract revenue from collaboration received from the sale of the Japan royalty rights of Nexavar® (sorafenib) tablets.

  • Revenue from the Nexavar collaboration agreement for the full year and fourth quarter of 2012 was $288.4 million and $72.9 million, respectively, as compared to $287.0 million and $76.8 million for the comparable periods in 2011. The increase in full year revenue from collaboration is primarily a result of increased Nexavar net sales as recorded by Bayer, excluding Japan, of $861.4 million and $229.1 million for the full year and fourth quarter of 2012, respectively, as compared to $839.9 million and $231.5 million for the full year and fourth quarter of 2011. The increase in full year Nexavar sales was driven by increased sales in the U.S. and demand driven growth in emerging markets including Asia Pacific and Latin America.
  • Kyprolis® (carfilzomib) for Injection net sales for the full year and fourth quarter of 2012 were $64.0 million and $45.3 million, respectively, representing orders shipped to and received by end customers such as physician offices and hospitals post-approval. The U.S. Food and Drug Administration (FDA) granted accelerated approval of Kyprolis on July 20, 2012. In addition, Onyx recorded deferred revenue of $9.8 million as of December 31, 2012, representing Kyprolis inventory at distributors which has not yet shipped to physician offices and hospitals.
  • Stivarga® (regorafenib) tablets royalty revenue was $8.3 million and $8.2 million for the full year and fourth quarter of 2012, respectively, following marketing approval by the U.S. FDA on September 27, 2012. Onyx receives a 20% royalty on Bayer's global net sales of Stivarga in human oncology.

Operating Expenses
Non-GAAP cost of goods sold was $1.3 million and $0.8 million for the full year and fourth quarter 2012, respectively. Cost of goods sold related to sales of Kyprolis is not representative of Onyx's future expectations of cost of goods sold because product costs associated with Kyprolis sales in 2012 were charged to research and development expense in periods prior to approval.

Non-GAAP research and development expense was $316.0 million and $80.3 million for the full year and fourth quarter 2012, respectively, compared to $249.1 million and $82.5 million for the same periods in 2011. Higher research and development expense between periods was primarily due to the global development of Kyprolis, particularly the ongoing Phase 3 ASPIRE, FOCUS and ENDEAVOR trials. On a GAAP basis, research and development expense was $325.3 million and $82.6 million for the full year and fourth quarter 2012, respectively, compared to $268.1 million and $84.0 million for the same periods in 2011.

Non-GAAP selling, general and administrative expense was $198.1 million and $68.0 million for the full year and fourth quarter 2012, respectively, compared to $147.8 million and $50.1 million for the same periods in 2011. Higher selling, general and administrative expense between periods was primarily related to hiring of the field force associated with the Kyprolis commercial launch as well as promotional costs. On a GAAP basis, selling, general and administrative expense was $224.2 million and $74.6 million for the full year and fourth quarter 2012, respectively, compared to $168.0 million and $52.6 million for the same periods in 2011.

Onyx recorded contingent consideration expense of $69.2 million and $2.9 million for the full year and fourth quarter 2012, respectively, compared to a benefit of $93.5 million and $116.7 million for the same periods in 2011. The increase in contingent consideration expense for the full year was primarily a result of the accelerated approval of Kyprolis.

Amortization expense for certain acquired intangible assets was $9.3 million and $5.2 million for the full year and fourth quarter 2012, respectively, and reflects the amortization of a portion of the intangible asset, which was acquired in the 2009 acquisition of Proteolix, Inc.

Provision for Income Taxes
Provision for income taxes for the full year 2012 primarily consisted of a $96.8 million non-cash tax benefit to recognize a change in the net deferred tax balance related to the U.S. approval of Kyprolis.

Cash, Cash Equivalents and Marketable Securities
On December 31, 2012, cash, cash equivalents and current and non-current marketable securities were $492.8 million, compared to $668.4 million at December 31, 2011. This decrease was largely due to Kyprolis development and commercialization expenses, partly offset by cash proceeds from the exercise of employee stock options. During January 2013, Onyx raised approximately $352 million in net proceeds from a public offering of 4.4 million shares of common stock.

Non-GAAP Financial Measures
This press release includes the following non-GAAP financial measures: non-GAAP net income (loss), non-GAAP net income (loss) - diluted, non-GAAP net income (loss) per share, non-GAAP net income (loss) per share - diluted, non-GAAP cost of goods sold, non-GAAP research and development expense and non-GAAP selling, general and administrative expense. The following table reconciles these non-GAAP measures to the most comparable financial measures calculated in accordance with GAAP.

Onyx management uses these non-GAAP financial measures to monitor and evaluate our operating results and trends on an on-going basis, and internally for operating, budgeting and financial planning purposes. Onyx management believes the non-GAAP information is useful for investors by offering the ability to better identify trends in our business and better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expense that affect Onyx. These non-GAAP financial measures are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP. A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Financial Measures."

Non-GAAP operating expenses exclude contingent consideration expense (benefit), employee stock-based compensation expense, imputed interest related to the convertible senior notes due 2016, the write-off of certain research and development expenses, equity investment impairment, the impact of the S*BIO termination, lease termination exit costs, amortization of certain acquired intangibles and related tax impact of certain acquired intangible assets.

Management Conference Call Today
Onyx will host a webcast and conference call with management to discuss full year and fourth quarter 2012 financial results, as well as provide a general business overview, today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

To access a live audio webcast of the conference call, log onto the Company's website at: http://www.onyx.com/investors/event-calendar

To access the live conference call, dial 847-585-4405 and use the passcode 34138405#. A replay of the call will be available on the Onyx website, or by dialing 630-652-3042 and using the passcode 34138405# beginning approximately one hour after the teleconference concludes through March 7, 2013.

About Nexavar® (sorafenib) tablets
Nexavar is approved in the U.S. for the treatment of patients with unresectable hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma.

For information about Nexavar, including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Kyprolis® (carfilzomib) for Injection
Kyprolis® (carfilzomib) for Injection is approved in the U.S. for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval was based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.

Full prescribing information is available at http://www.kyprolis.com.

About Stivarga® (regorafenib) tablets
Stivarga is approved in the U.S. for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.

For full prescribing information, including BOXED WARNINGS, visit www.stivarga-us.com.

About Onyx Pharmaceuticals, Inc.

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The Company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the Company's website at www.onyx.com.

Forward-Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding our expected financial results for 2013, the anticipated growth of our business, investments in and launch of Kyprolis, development of our oral proteasome inhibitor oprozomib, global expansion, generation of cash flows from sales of Nexavar, commercial, regulatory, and clinical results and milestones, royalties on Bayer's global net sales and development of Stivarga, promotion of Stivarga in the U.S., overall costs from sales of Kyprolis and our future clinical trials. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar® (sorafenib) tablets, Kyprolis® (carfilzomib) for Injection and Stivarga® (regorafenib) tablets being the only approved products from which we may obtain revenue; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; supply of Nexavar, Stivarga or Kyprolis; market acceptance and the rate of adoption of Nexavar, Stivarga and Kyprolis; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, Stivarga or Kyprolis; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; and product liability risks. Reference should be made to Onyx's Prospectus Supplement dated January 16, 2013 to Prospectus dated January 15, 2013 filed with the Securities and Exchange Commission (the "Commission") on January 17, 2013, as updated by Onyx's subsequent filings with the Commission, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Kyprolis® (carfilzomib) for Injection
Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.
Stivarga® (regorafenib) is a Bayer compound being developed by Bayer. Onyx receives a 20% royalty on global net sales in human oncology. Bayer and Onyx are jointly promoting Stivarga in the U.S.


                         ONYX PHARMACEUTICALS, INC.
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                  (In thousands, except per share amounts)
                             (unaudited)

                                  Three Months Ended        Year Ended
                                     December 31,          December 31,
                                 --------------------  --------------------
                                    2012       2011       2012       2011
                                 ---------  ---------  ---------  ---------
Revenue:
Revenue from collaboration
 agreement                       $  72,936  $  76,821  $ 288,416  $ 286,963
Product revenue                     45,319          -     63,955          -
Royalty revenue                      8,163          -      8,294          -
Contract revenue from
 collaborations                      1,500    160,211      1,500    160,211
                                 ---------  ---------  ---------  ---------
Total revenue                      127,918    237,032    362,165    447,174
                                 ---------  ---------  ---------  ---------

Operating expenses:
Cost of goods sold (excludes
 amortization of certain
 acquired intangible assets) (1)       832          -      1,328          -
Research and development (1)(2)     82,572     83,990    325,256    268,060
Selling, general and
 administrative (1)                 74,566     52,611    224,164    167,959
Contingent consideration expense
 (benefit)                           2,937   (116,663)    69,173    (93,468)
Lease termination exit costs             -     (4,540)         -      6,317
Intangible asset amortization        5,221          -      9,331          -
                                 ---------  ---------  ---------  ---------
Total operating expenses           166,128     15,398    629,252    348,868
                                 ---------  ---------  ---------  ---------
Income (loss) from operations      (38,210)   221,634   (267,087)    98,306
Investment income                      675        678      2,678      2,405
Interest expense (3)                (5,659)    (5,069)   (21,785)   (20,224)
Other income (expense) (4)            (728)      (326)     1,638     (4,103)
                                 ---------  ---------  ---------  ---------
Income (loss) before provision
 (benefit) for income taxes        (43,922)   216,917   (284,556)    76,384
Provision (benefit) for income
 taxes (5)                          (1,000)       242    (96,769)       274
                                 ---------  ---------  ---------  ---------
Net income (loss)                $ (42,922) $ 216,675  $(187,787) $  76,110
                                 =========  =========  =========  =========

Net income (loss) per share:
Basic                            $   (0.64) $    3.40  $   (2.88) $    1.20
                                 =========  =========  =========  =========
Diluted (6)                      $   (0.64) $    3.16  $   (2.88) $    1.19
                                 =========  =========  =========  =========

Computation of diluted shares:
Basic                               67,028     63,700     65,148     63,422
Dilutive effect of convertible
 senior notes                            -      5,801          -          -
Dilutive effect of options               -        629          -        588
                                 ---------  ---------  ---------  ---------
Diluted (6)                         67,028     70,130     65,148     64,010
                                 =========  =========  =========  =========


(1) Includes employee stock-based compensation charges of:


                                  Three Months Ended        Year Ended
                                     December 31,          December 31,
                                 --------------------  --------------------
                                    2012       2011       2012       2011
                                 ---------  ---------  ---------  ---------
Cost of goods sold               $       4  $       -  $       6  $       -
Research and development             2,255      1,461      9,296      6,269
Selling, general, and
 administrative                      6,568      2,556     26,024     20,121
                                 ---------  ---------  ---------  ---------
Total employee stock-based
 compensation                    $   8,827  $   4,017  $  35,326  $  26,390
                                 =========  =========  =========  =========

(2) Includes a $12.7 million non-cash expense related to the unamortized balance of funding provided to S*BIO which was recorded in the first quarter of 2011.

(3) Includes $11.5 million and $3.0 million imputed interest expense recorded for the full year and fourth quarter in 2012, related to the convertible senior notes due 2016. For the comparable periods in 2011, imputed interest expense was $10.2 million and $2.6 million.

(4) Includes a $0.5 million impairment charge which reflects the write off of Onyx's equity investment in S*BIO which was recorded in the third quarter of 2012 and $4.1 million net proceeds received pursuant to the sale of Jak2 inhibitors by S*BIO during the year ended December 31, 2012. In 2011, a $3.8 million impairment charge was recorded which reflected the reassessment of the fair value of Onyx's equity investment in S*BIO.

(5) Includes a $96.8 million and $1.1 million tax benefit representing the non-cash tax related effect on certain acquired intangible assets for the full year and fourth quarter of 2012, respectively.

(6) Under the "if-converted" method, interest and issuance costs and potential common shares related to the Company's convertible senior notes were excluded in the computation of diluted per share amounts for the three months ended December 31, 2012, and the years ended December 31, 2012 and 2011 because their effect would be anti-dilutive.


                         ONYX PHARMACEUTICALS, INC.
           RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
                  (In thousands, except per share amounts)
                             (unaudited)

                                  Three Months Ended        Year Ended
                                     December 31,          December 31,
                                 --------------------  --------------------
                                    2012       2011       2012       2011
                                 ---------  ---------  ---------  ---------


(i) Net income
  Net income (loss) - GAAP       $ (42,922) $ 216,675  $(187,787) $  76,110
  Non-GAAP adjustments:
    Contingent consideration
     expense (benefit) (a)           2,937   (116,663)    69,173    (93,468)
    Employee stock-based
     compensation (b)                8,827      4,017     35,326     26,390
    Imputed interest related to
     the convertible senior
     notes due 2016 (c)              3,009      2,605     11,511     10,191
    Advance funding to S*BIO (d)         -          -          -     12,666
    Impairment of equity
     investment in S*BIO (d)             -        750        500      3,750
    Proceeds received pursuant
     to the sale of Jak2
     inhibitors by S*BIO (e)             -          -     (4,096)         -
    Lease termination exit costs
     (f)                                 -     (4,540)         -      6,317
    Amortization of certain
     acquired intangible assets
     (g)                             5,221          -      9,331          -
    Non-cash tax related effect
     on certain acquired
     intangible assets (h)          (1,066)         -    (96,843)         -
                                 ---------  ---------  ---------  ---------
  Net income (loss) - Non-GAAP   $ (23,994) $ 102,844  $(162,885) $  41,956
                                 =========  =========  =========  =========

(ii) Cost of goods sold
  Cost of goods sold - GAAP      $     832  $       -  $   1,328  $       -
  Non-GAAP adjustments:
    Employee stock-based
     compensation (b)                   (4)         -         (6)         -
                                 ---------  ---------  ---------  ---------
  Cost of goods sold - Non-GAAP  $     828  $       -  $   1,322  $       -
                                 =========  =========  =========  =========

(iii) Research and development
 expenses
  Research and development
   expenses - GAAP               $  82,572  $  83,990  $ 325,256  $ 268,060
  Non-GAAP adjustments:
    Employee stock-based
     compensation(b)                (2,255)    (1,461)    (9,296)    (6,269)
    Advance funding to S*BIO (d)         -          -          -    (12,666)
                                 ---------  ---------  ---------  ---------
  Research and development
   expenses - Non-GAAP           $  80,317  $  82,529  $ 315,960  $ 249,125
                                 =========  =========  =========  =========

(iv) Selling, general and
 administrative expenses
  Selling, general and
   administrative expenses -
   GAAP                          $  74,566  $  52,611  $ 224,164  $ 167,959
  Non-GAAP adjustments:
    Employee stock-based
     compensation (b)               (6,568)    (2,556)   (26,024)   (20,121)
                                 ---------  ---------  ---------  ---------
  Selling, general &
   administrative expenses -
   Non-GAAP                      $  67,998  $  50,055  $ 198,140  $ 147,838
                                 =========  =========  =========  =========

(v) Earnings per share
                                 ---------  ---------  ---------  ---------
  Net income (loss) - Non-GAAP   $ (23,994) $ 102,844  $(162,885) $  41,956
                                 =========  =========  =========  =========
  Add:
    Interest and issuance costs
     related to dilutive
     convertible senior notes
     (i)                                 -      2,456          -          -
                                 ---------  ---------  ---------  ---------
  Net income (loss) - diluted -
   Non-GAAP                      $ (23,994) $ 105,300  $(162,885) $  41,956
                                 =========  =========  =========  =========

  Computation of non-GAAP
   diluted shares
  Basic shares - GAAP               67,028     63,700     65,148     63,422
  Dilutive effect of options and
   restricted stock                      -        629          -        588
  Dilutive effect of convertible
   senior notes (i)                      -      5,801          -          -
                                 ---------  ---------  ---------  ---------
  Diluted shares - Non-GAAP         67,028     70,130     65,148     64,010
                                 =========  =========  =========  =========

  Net income (loss) per share -
   Non-GAAP                      $   (0.36) $    1.61  $   (2.50) $    0.66
                                 =========  =========  =========  =========
  Net income (loss) per share -
   diluted - Non-GAAP            $   (0.36) $    1.50  $   (2.50) $    0.66
                                 =========  =========  =========  =========



                         ONYX PHARMACEUTICALS, INC.
           RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

These non-GAAP financial measures exclude the following items:

(a) Contingent consideration expense (benefit): The effects of contingent consideration expense (benefit) are excluded due to the nature of this charge, which is related to the change in fair value of the liability for contingent consideration in connection with the acquisition of Proteolix; such exclusion facilitates comparisons of Onyx's operating results to peer companies.

(b) Employee stock-based compensation: The effects of employee stock-based compensation are excluded because of varying available valuation methodologies, subjective assumptions and the variety of award types; such exclusion facilitates comparisons of Onyx's operating results to peer companies.

(c) Imputed interest related to the convertible senior notes due 2016: The effects of imputed interest related to the convertible senior notes due 2016 are excluded because this expense is non-cash; such exclusion facilitates comparisons of Onyx's cash operating results to peer companies.

(d) Advance funding to S*BIO and impairment of equity investment in S*BIO: The effects of the termination of the S*BIO collaboration agreement are excluded because they do not relate to the normal and recurring transactions of Onyx's business; such exclusion allows for a better representation of the ongoing economics of the business, facilitates comparison to peer companies and is reflective of how Onyx manages the business.

(e) Proceeds received pursuant to the sale of Jak2 inhibitors by S*BIO: The effects of the proceeds received pursuant to the sale of Jak2 inhibitors by S*BIO are excluded because they do not relate to the normal and recurring transactions of Onyx's business; such exclusion allows for a better representation of the ongoing economics of the business, facilitates comparison to peer companies and is reflective of how Onyx manages the business.

(f) Lease termination exit costs: The effects of lease termination exit costs and reoccupation of facilities are excluded because they represent non-cash items that relate to Onyx's exit from facilities it previously occupied in Emeryville and in South San Francisco, California.

(g) Amortization of certain acquired intangible assets: The effects of amortization of certain acquired intangible assets are excluded because this expense is non-cash; such exclusion facilitates comparisons of Onyx's operating results to peer companies.

(h) Non-cash tax related effect on certain acquired intangible assets: The tax related effect on certain acquired intangible assets is excluded because this expense is non-cash; such exclusion facilitates comparisons of Onyx's operating results to peer companies.

(i) Under the "if-converted" method, interest and issuance costs and potential common shares related to the Company's convertible senior notes were excluded in the computation of diluted per share amounts for the three months ended December 31, 2012 and the years ended December 31, 2012 and 2011 because their effect would be anti-dilutive.


                         ONYX PHARMACEUTICALS, INC.
             CALCULATION OF REVENUE FROM COLLABORATION AGREEMENT
                          (In thousands, unaudited)

                                      Three Months Ended      Year Ended
                                         December 31,        December 31,
                                     ------------------- -------------------
                                        2012      2011      2012      2011
                                     --------- --------- --------- ---------
Nexavar revenue subject to profit
 sharing (as recorded by Bayer)      $ 229,060 $ 231,490 $ 861,443 $ 839,944
Combined cost of goods sold,
 distribution, selling, general and
 administrative expenses                91,869    94,697   326,223   335,471
                                     --------- --------- --------- ---------
Combined collaboration commercial
 profit                              $ 137,191 $ 136,793 $ 535,220 $ 504,473
                                     ========= ========= ========= =========

Onyx's share of collaboration
 commercial profit                   $  68,596 $  68,396 $ 267,610 $ 252,236
Reimbursement of Onyx's shared
 marketing expenses                      4,340     5,255    20,806    22,946
Royalty revenue (1)                          -     3,170         -    11,781
                                     --------- --------- --------- ---------
Revenue from collaboration agreement $  72,936 $  76,821 $ 288,416 $ 286,963
                                     ========= ========= ========= =========


(1) Effective January 1, 2012, royalty revenue ceased due to the sale of the Japan royalty to Bayer.



                         ONYX PHARMACEUTICALS, INC.
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                               (In thousands)

                                                  December 31,
                                                      2012      December 31,
                                                  (unaudited)     2011(1)
                                                 ------------- -------------
Assets
Cash, cash equivalents and current marketable
 securities                                      $     484,436 $     646,343
Accounts receivable, net                                79,117             -
Other current assets                                   121,320        85,506
                                                 ------------- -------------
Total current assets                                   684,873       731,849
Marketable securities, non-current                       8,323        22,102
Property and equiment, net                              29,016        19,734
Finite-lived intangible assets, net                    257,969             -
Intangible assets - in-process research and
 development                                           171,500       438,800
Goodwill                                               193,675       193,675
Other assets                                             6,215         5,564
                                                 ------------- -------------
Total assets                                     $   1,351,571 $   1,411,724
                                                 ============= =============

Liabilities and stockholders' equity
Current liabilities                              $     131,369 $     111,792
Convertible senior notes due 2016                      174,404       162,893
Liability for contingent consideration, non-
 current                                               149,162       137,816
Deferred tax liability                                  51,940       149,413
Other long-term liabilities                             24,577        26,397
Stockholders' equity                                   820,119       823,413
                                                 ------------- -------------
Total liabilities and stockholders' equity       $   1,351,571 $   1,411,724
                                                 ============= =============

(1) Derived from the audited financial statements, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011. Certain amounts have been reclassified to conform to the current year presentation.


Contact: